Yuanye Sun

DAFNA Capital employs fundamental analysis and event-driven strategies to make long and short investments in publicly traded biotechnology and medical device companies. The firm seeks capital preservation and strong annualized return over longer time periods with minimum risk. Investment returns are generated as a product of recognizing their responsibility to improve human health through the efficient allocation of capital to the most promising preventive, diagnostic, and therapeutic interventions. The majority of their investments are in small/mid-cap companies with a focused pipeline or business and are based in the US or other developed countries.